CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022
-
5 06 2022
-
-
Source: MMWR Morbidity Mortal Weekly Rep. 71(18):633-637
[PDF-127.12 KB]
Details:
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Personal Author:
-
Description:Nursing home residents have experienced disproportionally high levels of COVID-19-associated morbidity and Mortality and were prioritized for early COVID-19 vaccination (1). Following reported declines in vaccine-induced immunity after primary series vaccination, defined as receipt of 2 primary doses of an mRNA vaccine (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) or 1 primary dose of Ad26.COV2 (Johnson & Johnson [Janssen]) vaccine (2), CDC recommended that all persons aged ≥12 years receive a COVID-19 booster vaccine dose.* Moderately to severely immunocompromised persons, a group that includes many nursing home residents, are also recommended to receive an additional primary COVID-19 vaccine dose.| Data on vaccine effectiveness (VE) of an additional primary or booster dose against infection with SARS-CoV-2 (the Virus that causes COVID-19) among nursing home residents are limited, especially against the highly transmissible B.1.1.529 and BA.2 (Omicron) Variantss. Weekly COVID-19 Surveillance and vaccination coverage data among nursing home residents, reported by skilled nursing facilities (SNFs) to CDC's National Healthcare Safety Network (NHSN)| during February 14-March 27, 2022, when the Omicron Variants accounted for >99% of sequenced isolates, were analyzed to estimate relative VE against infection for any COVID-19 additional primary or booster dose compared with primary series vaccination. After adjusting for calendar week and variability across SNFs, relative VE of a COVID-19 additional primary or booster dose was 46.9% (95% CI = 44.8%-48.9%). These findings indicate that among nursing home residents, COVID-19 additional primary or booster doses provide greater protection against Omicron Variants infection than does primary series vaccination alone. All immunocompromised nursing home residents should receive an additional primary dose, and all nursing home residents should receive a booster dose, when eligible, to protect against COVID-19. Efforts to keep nursing home residents up to date with vaccination should be implemented in conjunction with other COVID-19 Prevention strategies, including tTesting and vaccination of nursing home staff members and visitors.
-
Subjects:
-
Source:
-
Series:
-
DOI:
-
ISSN:0149-2195 (print);1545-861X (digital);
-
Pubmed ID:35511708
-
Pubmed Central ID:PMC9098239
-
Document Type:
-
Place as Subject:
-
Pages in Document:5 pdf pages
-
Volume:71
-
Issue:18
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
